RUNX1 and acute myeloid leukemia: In addition, a combination of dexamethasone with cytarabine or doxorubicin was synergistic in this AML cell line, which suggests that combining dexamethasone with “3+7” induction and then with high-dose cytarabine during the consolidation phase could be a treatment option to be explored in patients with t(8;21)/RUNX1-RUNX1T1 AML (100, 102).